JP2019517511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517511A5 JP2019517511A5 JP2018563090A JP2018563090A JP2019517511A5 JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5 JP 2018563090 A JP2018563090 A JP 2018563090A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- months
- expression pattern
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 15
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 15
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims 6
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022146466A JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345658P | 2016-06-03 | 2016-06-03 | |
| US62/345,658 | 2016-06-03 | ||
| PCT/US2017/035798 WO2017210624A1 (en) | 2016-06-03 | 2017-06-02 | Anti-pd-1 antibody for use in a method of treating a tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Division JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517511A JP2019517511A (ja) | 2019-06-24 |
| JP2019517511A5 true JP2019517511A5 (cg-RX-API-DMAC7.html) | 2020-07-09 |
Family
ID=59067919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563090A Pending JP2019517511A (ja) | 2016-06-03 | 2017-06-02 | 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 |
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200325226A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3464369A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019517511A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20250107295A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109476753A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017210624A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| LT3377534T (lt) | 2015-11-18 | 2025-08-11 | Bristol-Myers Squibb Company | Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį |
| CN110678483B (zh) | 2017-06-01 | 2023-09-22 | 百时美施贵宝公司 | 用抗pd-1抗体治疗肿瘤的方法 |
| WO2019157124A1 (en) * | 2018-02-08 | 2019-08-15 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
| CA3090995A1 (en) * | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti-pd-1 antibodies |
| MA51844A (fr) * | 2018-02-13 | 2021-05-19 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
| WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| WO2020139941A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Treatment of stk11-loss cancers |
| EP3946625A1 (en) * | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2021034890A1 (en) * | 2019-08-19 | 2021-02-25 | Pandion Therapeutics, Inc. | Targeted immunotolerance with a pd-1 agonist |
| EP4387104A1 (en) | 2022-12-13 | 2024-06-19 | LX Semicon Co., Ltd. | Analog-to-digital converter and semiconductor device having the same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2981821B2 (en) * | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| KR102243062B1 (ko) * | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| ES2753360T3 (es) * | 2014-05-29 | 2020-04-08 | Spring Bioscience Corp | Anticuerpos contra PD-L1 y usos de los mismos |
| SG10201807625PA (en) * | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
-
2017
- 2017-06-02 US US16/306,380 patent/US20200325226A1/en not_active Abandoned
- 2017-06-02 WO PCT/US2017/035798 patent/WO2017210624A1/en not_active Ceased
- 2017-06-02 KR KR1020257022183A patent/KR20250107295A/ko active Pending
- 2017-06-02 JP JP2018563090A patent/JP2019517511A/ja active Pending
- 2017-06-02 KR KR1020237026427A patent/KR20230118713A/ko not_active Ceased
- 2017-06-02 KR KR1020187038120A patent/KR20190015408A/ko not_active Ceased
- 2017-06-02 EP EP17730636.2A patent/EP3464369A1/en active Pending
- 2017-06-02 CN CN201780048321.0A patent/CN109476753A/zh active Pending
-
2022
- 2022-03-21 US US17/699,949 patent/US20220315657A1/en not_active Abandoned
- 2022-09-14 JP JP2022146466A patent/JP2022188071A/ja active Pending
-
2025
- 2025-02-14 JP JP2025022545A patent/JP2025081454A/ja active Pending
- 2025-05-20 US US19/213,805 patent/US20250382368A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517511A5 (cg-RX-API-DMAC7.html) | ||
| Stuurman et al. | Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement | |
| Zhao et al. | Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Dhillon | Palbociclib: first global approval | |
| Jhaveri et al. | Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions | |
| Murphy et al. | The role of CDK4/6 inhibition in breast cancer | |
| JP2019517498A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517504A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508516A5 (cg-RX-API-DMAC7.html) | ||
| Villanueva et al. | A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study | |
| JP2019517512A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521087A5 (cg-RX-API-DMAC7.html) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019517505A5 (cg-RX-API-DMAC7.html) | ||
| Hwang et al. | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer | |
| JP2019536805A5 (cg-RX-API-DMAC7.html) | ||
| JP2019503365A5 (cg-RX-API-DMAC7.html) | ||
| JP2018512391A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) | |
| JP2019530713A5 (cg-RX-API-DMAC7.html) | ||
| Novello et al. | A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer | |
| Chiappori et al. | Obatoclax mesylate, a Pan–Bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non–small-cell lung cancer | |
| Rugo et al. | A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer | |
| Ramaswamy et al. | A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors |